Epilepsy Market Synopsis
Epilepsy is a major neurological disorder in which the brain activity becomes abnormal causing periods of unusual behavior and sensations. The disorder is noticeable in young children and young adults. Moreover, brain injuries which can trigger post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) can fuel the demand in the epilepsy market.
The Global Epilepsy Market is projected to touch a valuation of USD 9,509.2 million by 2023, exhibiting a CAGR of 8.20% over the forecast period (2018-2023). High prevalence of epilepsy among the geriatric population and increase in cases of brain injuries caused by accidents are major factors driving market growth.
Free Sample at https://www.marketresearchfuture.com/sample_request/7730
The high susceptibility rate of attaining epilepsy among the elderly is projected to drive market demand. As per the 2018 study in the Neuroepidemiology Journal, the prevalence rate of epilepsy among individuals older than 60 was 7.7 per 1000.
Developing economies in Africa offer a prime opportunity for investment in the market. According to a report by the World Health Organization (WHO) in 2017, nearly 80% of the patient population with epilepsy live in middle- and low-income countries. Manufacturers of epileptic drugs can capitalize on the opportunity to invest and establish facilities to cater to the growing demand.
Key players in the epilepsy market include,
Eisai Co. Ltd. (Japan)
Novartis AG (Switzerland)
Pfizer Inc. (US)
GW Pharmaceuticals PLC (UK)
Abbott Laboratories (US)
UCB SA (Belgium)
LivaNova PLC (UK)
Medtronic PLC (Ireland)
Johnson & Johnson Services Inc. (US)
GlaxoSmithKline PLC (UK)
and NeuroPace Inc. (US).
Epilepsy Market Segmentation
The global epilepsy market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the epilepsy market.
By diagnosis & treatment, the treatment segment held 66.2% share of the epilepsy market in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.
By end-user, hospitals were the largest segment of the market with a valuation of USD 1,739.22 million in 2017. It is projected to exhibit a stellar 8.29% CAGR over the forecast period. On the other hand, clinics can showcase higher CAGR of 8.93% during the assessment period owing to clinics being a preferred center for diagnosis and treatment. In addition, adoption of latest equipment by doctors to provide excellent patient care can spur the growth of the segment.
Access Complete Premium Research Report at https://www.marketresearchfuture.com/reports/epilepsy-market-7730
Global Epilepsy Market Regional Summary
Region-wise, the epilepsy market is segmented into Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). Among them, the Americas accounted for 41% share in 2017, followed by Europe, APAC, and MEA.
Europe is expected to exhibit 8.31% CAGR over the forecast period. Increased investment in research and development of effective drugs to treat epilepsy coupled with high incidence of the disorder are factors projected to drive regional market growth exponentially.
APAC epilepsy market is set to touch a valuation of USD 2,046.57 million by 2023 due to high incidence of the disorder registered in the region. In addition, countries of India, South Korea, and China emerging as viable destinations for testing and development of novel drugs can spur market demand over the forecast period.
List of Tables
Table 1 Market Synopsis
Table 2 Primary Interviews
Table 3 Global Epilepsy Market, By Condition, 2015–2023 (USD Million)
Table 4 Global Epilepsy Market, For Epilepsy Drug-Resistant/ Intractable Epilepsy, By Region 2015–2023 (USD Million)
Table 5 Global Epilepsy Market, For Others, By Region 2015–2023 (USD Million)
Table 6 Global Epilepsy Market, By Diagnosis & Treatment, 2015–2023 (USD Million)
Table 7 Global Epilepsy Market, For Diagnosis, By Region, 2015-2023 (USD Million)
Table 8 Global Epilepsy Market, For Treatment, By Region, 2015-2023 (USD Million)
Table 9 Global Epilepsy Market, For Diagnosis, By Type 2015–2023 (USD Million)
Table 10 Global Epilepsy Market, For Imaging Devices, By Type 2015–2023 (USD Million)
…To be Continued.
Get an Instant Discount at https://www.marketresearchfuture.com/check-discount/7730
About Market Research Future: MRFR, we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar